Kadmos Capital Ltd

🎉 Great news from Jua! 🎉 CB Insights named Jua.ai one of the 100 most promising AI companies in the world in 2024! This nomination reflects our commitment to innovating AI for energy trading and the natural world. The 100 winners were chosen based on several factors including, analyst briefings, market feedback, the team's strength, investor strength, and CB Insights Mosaic scores. Find details on the nomination and the list of the 100 winners via the link in the comments 🌐 #Jua #AI100

💥 #IWD2024 “Progress begins with the audacity of women who refuse to conform. Here's to shaping a future where every woman feels empowered to lead.“ Nikolina Lauc, Founder & CEO of GlycanAge #KadmosCapitalPortfolio #KadmosCapital #Glycanage #InternationalWomensDay #FemaleFounders 

💥 “GlycanAge’s vision lies at the crossroad between preventive medicine, longevity and diagnostics. We are delighted to back Nikolina Lauc and Dr. Gordan Lauc in their mission and are confident they will leave a mark on the future of healthcare” John Gebeily - Partner, Kadmos Capital Meet GlycanAge. GlycanAge is a leading biotech company specializing in glycobiology and the science of biological aging. With its innovative biological age test, GlycanAge is pioneering personalized preventive healthcare, enabling individuals to make informed decisions about their health and lifestyle. GlycanAge has just successfully completed its $4.2 million seed funding round, led by Kadmos Capital and LAUNCHub Ventures. #KadmosCapitalPortfolio #KadmosCapital #Glycanage #TechBio

💥 “GlycanAge’s vision lies at the crossroad between preventive medicine, longevity and diagnostics. We are delighted to back Nikolina Lauc and Dr. Gordan Lauc in their mission and are confident they will leave a mark on the future of healthcare” John Gebeily - Partner, Kadmos Capital Meet GlycanAge. GlycanAge is a leading biotech company specializing in glycobiology and the science of biological aging. With its innovative biological age test, GlycanAge is pioneering personalized preventive healthcare, enabling individuals to make informed decisions about their health and lifestyle. GlycanAge has just successfully completed its $4.2 million seed funding round, led by Kadmos Capital and LAUNCHub Ventures. #KadmosCapitalPortfolio #KadmosCapital #Glycanage #TechBio

As seen in The Times, #KadmosCapitalPortfolio iFAST Diagnostics “A spinout from University of Southampton, iFast is seeking to help solve one of the biggest threats to world health: antibiotic resistance.” Learn more here: https://lnkd.in/eCa9FGBD #KadmosCapitalPortfolio #KadmosCapital #IFastDiagnostics #InThePress